First offer ($2.1bn) for J&J’s LifeScan

Platinum Equity, a private equity with $ 13 billion of assets, has submitted a $2.1bn offer to the US-based group Johnson & Johnson  for its LifeScan arm, focused on the diabetes area. The LifeScan unit, headquartered in Chesterbrook (Pennsylvania) and Zug (Switzerland) manufactures and markets blood sugar meters and generated revenues of $1.5bn in 2017. J&J in late 2016 informed investors and analysts that it was assessing strategic options for its three units operating in the diabetes sector–LifeScan, Animas Corporation and Calibra Medical.

(Source: Platinum Equity)